CRSP
Crispr Therapeutics AG
55.30$
-1.2%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
Crispr Therapeutics AG (CRSP) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -192 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -40 | -96 | 110 | -96 | -107 | -50 | -54 | -114 | -85 | -93 | -109 | -192 | -478 | |
| 4.9 | 4.9 | 4.8 | 4.8 | 4.7 | 4.8 | 4.7 | 4.6 | 4.4 | 5.7 | 4.3 | 8.6 | 23 | |
| 20 | 18 | 19 | 24 | 22 | 22 | 20 | 18 | 17 | 18 | 16 | 34 | 85 | |
| 53 | -204 | 210 | 10 | -40 | -24 | 55 | -17 | 11 | 23 | -15 | -19 | -1.0 | |
| 2.1 | 0.7 | 0.7 | 0.7 | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.5 | 0.5 | 1.2 | 2.2 | |
| 121 | -81 | -98 | -127 | -162 | 106 | -20 | 70 | -119 | 37 | -411 | -466 | -959 | |
| – | – | – | -0.5 | 0.5 | – | – | 71 | 71 | – | – | -0.7 | – | |
| 1.6 | 39 | 306 | -0.5 | 9.6 | 17 | 11 | 2.3 | 297 | 116 | 592 | 599 | 1,604 | |
| 83 | -138 | 318 | -223 | -259 | 73 | -63 | -42 | 93 | 61 | 69 | -60 | 163 | |
| -42 | -97 | 109 | -96 | -107 | -50 | -54 | -114 | -85 | -93 | -109 | -194 | -481 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.